Printer's No. PN2835
See other bills
under the
same topic PRINTER'S NO. 2835 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE BILL No.2181 Session of 2026 INTRODUCED BY PIELLI, MUNROE, McNEILL, HILL-EVANS, SANCHEZ, BRENNAN, D. WILLIAMS, O'MARA, GREEN, HANBIDGE, DALEY, CEPEDA-FREYTIZ AND BOROWSKI, JANUARY 30, 2026 REFERRED TO COMMITTEE ON HEALTH, JANUARY 30, 2026 AN ACTAmending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for drug overdose medication.The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows:Section 1. Section 13.8(h) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, is amended to read:Section 13.8. Drug Overdose Medication.--* * *(h) As used in this section, the term "opioid antagonist" means a drug or device approved by the Federal Food, Drug, and Cosmetic Act (52 Stat. 1040, 21 U.S.C. § 301 et seq.) for emergency reversal of known or suspected opioid overdose, including naloxone hydrochloride, nalmefene hydrochloride or 12345678910111213141516171819202122 other similarly acting drugs approved by the United States Food and Drug Administration for the treatment of an opioid overdose.Section 2. This act shall take effect in 60 days.20260HB2181PN2835 - 2 - 123
under the
same topic PRINTER'S NO. 2835 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE BILL No.2181 Session of 2026 INTRODUCED BY PIELLI, MUNROE, McNEILL, HILL-EVANS, SANCHEZ, BRENNAN, D. WILLIAMS, O'MARA, GREEN, HANBIDGE, DALEY, CEPEDA-FREYTIZ AND BOROWSKI, JANUARY 30, 2026 REFERRED TO COMMITTEE ON HEALTH, JANUARY 30, 2026 AN ACTAmending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for drug overdose medication.The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows:Section 1. Section 13.8(h) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, is amended to read:Section 13.8. Drug Overdose Medication.--* * *(h) As used in this section, the term "opioid antagonist" means a drug or device approved by the Federal Food, Drug, and Cosmetic Act (52 Stat. 1040, 21 U.S.C. § 301 et seq.) for emergency reversal of known or suspected opioid overdose, including naloxone hydrochloride, nalmefene hydrochloride or 12345678910111213141516171819202122 other similarly acting drugs approved by the United States Food and Drug Administration for the treatment of an opioid overdose.Section 2. This act shall take effect in 60 days.20260HB2181PN2835 - 2 - 123
Texto oficial de la Legislatura de Pennsylvania. El formato se adaptó para leerlo en Ratifi.